drugset / Trial / NCT07347678
Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers
Phase 1
Recruiting
60 enrolled
Ikaria Bioscience Pty Ltd
Shanghai Rona Therapeutics Co., Ltd. · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN5681 in Adult healthy subjects
Timeline
- Start
- 2026-03-12
- Primary completion
- 2027-02
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RN5681 | Unknown | — | Subcutaneous |
Indications
No indication recorded.